IL22 and Alzheimer disease: It is interesting to note that among the markers most strongly reduced in their expression by dupilumab are cytokines produced by slanMo (TNF-α, IL-23p19, and IL-12/23p40) themselves or by T cells induced by slanMo (IL-17, IFN-γ, and IL-22) (14, 45), thereby indicating that slanMo can support an immune response with relevance to AD.